Projected return on investment in pharma research and development (R&D) in 2024 has risen to 5.9%, continuing the upward ...

Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.

Deloitte's Agentforce accelerators are transforming the way organizations operate and are designed to help clients scale ...

The Simulation CoE is newly integrated into existing Deloitte Experience Centers to offer clients immersive experiences, ...

Deloitte is making strides to become a key player in the space industry for government and commercial services.

Deloitte Touche Tohmatsu India LLP has entered into a strategic alliance with Zoho, a global technology company, aiming to accelerate digital tra ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

Through industry-specific solution development and joint go-to-market strategies, Deloitte India and Zoho aim to enable ...

Deloitte, in a series of annual reports on "Measuring the return from pharmaceutical innovation," in collaboration with other member firms, has provided insights into the state of biopharma R&D ...

The establishment of the CoE is part of Deloitte's portfolio of offerings to serve clients around the world through its global capability and innovation centers. The CoE will serve as a dynamic ...